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Abstract
Objective—The hypothalamic control of energy balance is regulated by a complex network of
neuropeptide-releasing neurons. Whilst the effect of these neuropeptides on individual aspects of
energy homeostasis has been studied, the coordinated response of these effects has not been
comprehensively investigated. We have simultaneously monitored a number of metabolic
parameters following ICV administration of 1nmol and 3nmol of neuropeptides with established
roles in the regulation of feeding, activity and metabolism. Ad libitum fed rats received the
orexigenic neuropeptides neuropeptide Y (NPY), agouti-related protein (AgRP), melanin-
concentrating hormone (MCH) or orexin-A. Overnight food deprived rats received an ICV
injection of the anorectic peptides α-MSH, corticotrophin releasing factor (CRF) or neuromedin U
(NMU).
Results—Our results reveal the temporal sequence of the effects of these neuropeptides on both
energy intake and expenditure, highlighting key differences in their function as mediators of
energy balance. NPY and AgRP increased feeding and decreased oxygen consumption, with the
effects of AgRP being more prolonged. In contrast, orexin-A increased both feeding and oxygen
consumption, consistent with an observed increase in activity. The potent anorexigenic effects of
CRF were accompanied by a prolonged increase in activity whilst NMU injection resulted in
significant but short-lasting inhibition of food intake, ambulatory activity and oxygen
consumption. Alpha-MSH injection resulted in significant increases in both ambulatory activity
and oxygen consumption, and reduced food intake following administration of 3nmol of the
peptide.
Conclusion—We have for the first time, simultaneously measured several metabolic parameters
following hypothalamic administration of a number of neuropeptides within the same
experimental system. This work has demonstrated the interrelated effects of these neuropeotides
on activity, energy expenditure and food intake thus facilitating comparison between the different
hypothalamic systems.
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Introduction
Energy balance in mammals is a highly regulated physiological process and is maintained by
a homeostatic system involving both the central nervous system (CNS) and the periphery.
The hypothalamus and the brainstem are CNS sites critical in the regulation of energy
homeostasis. Reciprocal neuronal connections exist between these two regions which, in
response to peripheral signals of nutritional status, regulate both short and long-term energy
homeostasis.
The hypothalamus contains an extensive neuronal network which releases neuropeptides in a
coordinated manner and contributes to the physiological responses to changes in nutritional
status. The regulation of energy homeostasis integrates energy intake - i.e. food intake - with
energy outputs such as resting metabolic rate, activity and thermogenesis. The neuropeptides
within the hypothalamus that regulate energy homeostasis specifically influence energy
intake and energy output to exert their overall effect on energy balance. Thus, determining
the coordinated effects of specific neuropeptides on energy intake, behavior and energy
expenditure is essential to understanding their physiological role.
The hypothalamic circuits controlling energy homeostasis are still to be precisely
determined. The best characterized neuronal populations involved in the regulation of
appetite and energy expenditure are the orexigenic neuropeptide Y (NPY)/ agouti-related
protein (AgRP) neuron and the anorexigenic pro-opiomelanocortin (POMC) neuron located
in the arcuate nucleus (Arc). The Arc is located at the base of the hypothalamus and is
incompletely isolated by the blood brain barrier. It is thus able to be directly influenced by
peripherally circulating signals of acute food intake and nutritional status. Neuronal
populations in the Arc respond to these circulating factors and signal to extra-hypothalamic
regions such as the brainstem, as well as other hypothalamic nuclei, including the
paraventricular nucleus (PVH) and lateral hypothalamic area (LHA), where they influence
second order neurons (1). These include melanin-concentrating hormone (MCH) and orexin-
A neurons, located primarily in the LHA (2;3), corticotrophin releasing factor (CRF)
neurons, found predominantly in the PVH (4) and neurons releasing neuromedin U (NMU),
which in turn interact with the NMU2R located in the PVH (5).
Whilst the effects of these neuropeptides on food intake and energy expenditure have been
studied, they have not been comprehensively and simultaneously measured in the same
experimental system. The Comprehensive Laboratory Animal Monitoring System (CLAMS)
(Columbus Instruments) enables 24 hour profiles of food intake, activity and energy
expenditure to be determined. Simultaneous measurements of food intake, activity and
energy expenditure allow the comprehensive metabolic effects of specific neuropeptides to
be determined.
To further understand the complex responses involved in appetite regulation, we studied the
role of the Arc neuropeptides NPY, AgRP, and α-MSH (a product of the POMC gene), the
predominantly PVH neuropeptides CRF and NMU, and the LHA neuropeptides MCH and
orexin-A in the regulation of energy balance. The coordinated effects of ICV administration
of these neuropeptides on food intake, oxygen consumption, respiratory exchange ratio
(RER) and activity were determined using the CLAMS. These comprehensive
measurements provide further insight into the roles of these peptides in the regulation of the
specific components of energy balance.
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Materials and Methods
Animals
Male Wistar rats (specific pathogen free; Charles River, Margate, UK), weighing 300-350 g,
were maintained in individual cages under controlled temperature (21 - 23 °C) and light
(12:12 light-dark cycle; lights on at 0700 h) with ad libitum access to food (RM1 diet, SDS
Ltd., Witham, UK) and water. Animal procedures were approved under the British Home
Office Animals (Scientific Procedures) Act 1986 (Project Licence 70/6402).
Materials
Cannulation materials were purchased from Plastics One, Inc. (Roanoke, VA, USA). Rat
CRF, orexin-A and α-MSH were synthesized by Bachem (St Helen’s, UK). NMU-23 was
synthesized by IAF Biochem International (Quebec, ON, Canada). MCH and AgRP
(83-132) were synthesized by the Peptide Institute (Osaka, Japan). NPY was synthesized as
previously described (6).
ICV cannulation and injection
Animals were implanted with a permanent 22 gauge stainless steel cannula projecting to the
third ventricle, as previously described (7). Animals were allowed seven days recovery after
surgery and were then accustomed to handling and being weighed on a daily basis. All
compounds were injected using a 28-gauge stainless steel injector placed in and projecting
1mm below the tip of the cannula. Cannula placement was confirmed by a positive
dipsogenic response to angiotensin II (50ng/rat). Only those animals with a positive
dipsogenic response were included in the data analysis. Three days after the angiotensin II
injection, all animals were habituated to the injection process by receiving a single injection
of 5μl saline injected over 1 minute as previously described (7).
Study design
ICV cannulated animals were monitored using a 24 chamber open-circuit Oxymax
Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus instruments,
Columbus, OH, USA). Individually housed rats were maintained at 21-23°C under a 12:12h
light-dark cycle (light period 0700-1900h). Powdered RM1 diet (SDS Ltd.) and water were
available ad libitum unless otherwise stated. Animals were individually housed in plexiglass
cages, through which air was passed at a flow rate of 2.5L/min. Prior to all metabolic cage
studies, rats were acclimatized to their cages for 48h in order to generate a stable metabolic
background against which to test the effects of the neuropeptides.
Baseline studies
In order to generate reference data for subsequent neuropeptide studies, baseline data was
recorded in ad libitum fed and food deprived animals. Ad libitum fed rats (n = 24) were
placed in the CLAMS metabolic cages for 48h and then food deprived for an additional 24h.
Metabolic parameters (VO2 and VCO2) were measured by indirect calorimetry. Exhaust air
from each chamber was sampled at 30min intervals for a period of 1min. Sample air was
sequentially passed through O2 and CO2 sensors (Columbus Instruments) for determination
of O2 and CO2 content. Oxygen consumption and CO2 production values were normalised
with respect to body weight and O2 consumption was corrected to metabolic body size
(W0.75) (8). RER was calculated by dividing VCO2 by VO2. Ambulatory activity of each
animal was measured simultaneously using the optical beam technique (Opto M3, Columbus
Instruments). Consecutive photo-beam breaks were scored as an ambulatory movement.
Activity counts in x and z axes were recorded every minute for 24h and were used to
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determine horizontal (XAMB) and vertical (ZTOT) movement respectively. Food intake
was measured every minute.
ICV injection studies
A dose of 3nmol has been previously demonstrated to cause a robust effect on food intake
for all neuropeptides examined in this study (5;6;9-12). Based on this data, we have
administered 1nmol and 3nmol of each peptide studied in order to facilitate direct
comparison of their effects. VCO2, VO2, activity (horizontal and vertical) and cumulative
food intake were monitored as described above.
Satiated studies
Ad libitum fed rats received a single ICV injection of either saline or peptide (NPY, AgRP,
MCH or orexin-A) (n = 8 per group) at doses of either 1nmol or 3nmol in the early light
phase (0900-1000h).
Food deprived studies
Rats were food deprived for 20h prior to injection. All rats received a single injection of
either saline or peptide (α-MSH, CRF or NMU) (n = 8 per group) at doses of 1nmol or
3nmol in the early light phase (0900-1000h). Animals were returned to their home cage with
ad libitum access to food.
Statistics
Statistical advice was provided by J. Eliahoo at the Statistical Advisory Service, Imperial
College London. For all parameters, differences between the treatment groups were
determined using the Mann-Whitney U test (Stata 9, Statacorp, College Station, TX, USA).
All significant effects of neuropeptides were recorded in the initial 12h post injection and
are presented as such, with the exception of AgRP which is shown as a 24h profile. In all
cases P < 0.05 was considered to be statistically significant. All feeding data are presented as
percentage of saline to facilitate comparison between different neuropeptide treatments.
Results
Twenty four hour baseline readings of food intake, activity and energy expenditure in ad
libitum fed and food deprived rats
Increased levels of feeding and locomotor activity occurred during the dark phase compared
to the light phase. These activities exhibited a bimodal pattern, with levels peaking at the
beginning and end of the dark phase (Figure 1). Corresponding with these diurnal variations,
VO2 and RER were also elevated during the dark phase whilst fasting resulted in a reduction
in VO2 and VCO2 during the dark phase (Figure 1).
NPY
ICV injection of either 1nmol or 3nmol NPY resulted in an immediate increase in food
intake, 5min (3nmol) and 10min (1nmol) post injection (Table 1, Figure 2). A significant
increase in XAMB was also observed by 1h post injection, with the 3nmol dose of NPY
causing a more sustained effect (Table 1, Figure 3). A similar pattern was also seen for
ZTOT (data not shown). Despite the increase in activity, ICV administration of either dose
of NPY caused a significant decrease in VO2 (Table 1, Figure 4), and a significant increase
in RER (Figure 5).
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AgRP
A single ICV injection of either 1nmol or 3nmol AgRP produced a significant increase in
food intake with the effect lasting throughout the remaining 24h measurement period (Table
1, Figure 2). During the dark phase, significant reductions in XAMB were observed in
AgRP injected animals (Table 1, Figure 3). These reductions in XAMB coincided with the
peaks in activity at the beginning and the end of the dark phase observed in saline injected
controls (Figure 3). A similar pattern was also seen in ZTOT (data not shown). There was a
trend towards a decrease in VO2 in AgRP treated animals compared to saline controls;
however, this did not achieve statistical significance (Figure 4). A significant increase in
RER was observed following administration of 1 or 3nmol AgRP (Figure 5).
Orexin-A
A trend towards an increase in food intake was observed for 3h following a single injection
of either 1nmol or 3nmol orexin-A. This effect, however, did not reach statistical
significance (Figure 2). In contrast to the non-significant effects on feeding, a rapid and
potent increase in locomotion was observed at both doses (Table 1, Figure 3). A similar
pattern was observed with ZTOT (data not shown). Consistent with the effects on activity,
an increase in VO2 was also observed at 1nmol and 3nmol doses. (Table 1, Figure 4). No
effect was seen on RER (Figure 5).
MCH
A trend towards a stimulation in feeding was observed at 30 minutes following a single ICV
injection of either dose of MCH; however, this effect did not reach statistical significance
(Supplementary Figure 1). A small decrease in VO2 at 30min post injection and a small rise
in RER lasting up to 4h post injection, neither of which reached statistical significance, were
also recorded (Supplementary Figure 1).
α-MSH
A single ICV injection of 3nmol α-MSH rapidly decreased food intake in food deprived rats
(Table 1, Figure 2). No statistically significant effects on food intake were observed with
1nmol α-MSH. There was a small but significant increase in XAMB at both 1nmol and
3nmol doses (Table 1, Figure 3). A similar pattern was observed for ZTOT (data not
shown). A rapid and dramatic increase in VO2 was observed by 30min post injection in
animals receiving either 1nmol or 3nmol α-MSH (Table 1, Figure 4). Injection of both
1nmol and 3nmol of α-MSH also resulted in a significantly reduced RER (Figure 5).
CRF
A rapid and potent reduction in food intake was seen following a single ICV injection of
either 1nmol or 3nmol CRF. Food intake was significantly lower than saline controls by
10min and 15min post injection for 1nmol and 3nmol respectively, and remained
significantly lower for the duration of the 24h measurement period (Table 1, Figure 2). The
decrease in food intake was accompanied by a prolonged stimulation of XAMB (Table 1,
Figure 3). A similar pattern was also observed for ZTOT (data not shown). In addition, an
increase in VO2 was also observed. This, however, was not as prolonged as the effect seen
on food intake and activity and was only significant from 30min to 1h post injection for both
doses (Table 1, Figure 4). RER was significantly reduced following administration of both
doses of CRF (Figure 5).
NMU
A single ICV injection of either 1nmol or 3nmol NMU significantly reduced food intake
(Table 1, Figure 2). A rapid and significant increase in XAMB was also observed (Table 1,
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Figure 3). A similar pattern was also observed for ZTOT (data not shown). In addition,
1nmol and 3nmol NMU significantly increased VO2 by 30min post injection (Table 1,
Figure 4). A small decrease in RER was also seen at 1h post injection, in accordance with
the reduction in food intake (Figure 5).
Discussion
Understanding the coordinated effects of neuropeptides involved in energy intake, behavior
and energy expenditure is necessary to determine their physiological role in the regulation of
energy homeostasis. The changes observed in energy expenditure in our studies are
influenced by alterations in physical activity, thermogenesis and food intake in rats. In a
food deprived state, energy expenditure and activity are reduced as a means of conserving
energy, whereas during feeding the opposite effect is observed. This change is reflected in
the altered RER values, indicating the metabolism of readily available carbohydrate in the
fed state compared to the utilization of fat stores in the food deprived state.
Under ad libitum fed conditions, rats on a 12 hour light:dark cycle consume most of their
daily food intake during the dark phase with peaks at the beginning and end of this period
(13;14). The increase in food intake at the beginning of the dark phase is thought to be due
to an energy deficiency from the preceding light phase during which food intake is relatively
low (15). The increase in food intake at the end of the dark phase may exist to ensure
sufficient energy availability throughout the light phase (16).
In the present study, all animals were injected in the early light phase. Orexigenic
neuropeptides were administered to ad libitum fed rats whilst anorectic neuropeptides were
injected in food deprived rats. These models were used in accord with work previously
published by ourselves and others (17-19). It has been shown, however, that the time of day
that a peptide is administered can have an effect on its potency and duration of action (20).
Had the rats been injected at different times during the light/dark cycle, for example, at the
beginning of the dark phase, different food intake, activity and energy expenditure profiles
may have been observed. Similarly administering the orexigenic neuropeptides to food
deprived rats and the anorectic neuropeptides to ad libitum fed rats would also likely have
resulted in different profiles. Thus while our experiments demonstrate the effects of the
neuropeptides in the same experimental system, their results cannot be assumed to be
applicable to rats injected under different experimental conditions.
Physiologically, neuropeptides are released in coordinated fashion in response to changes in
energy balance. It is possible to study the effects of administering more than one
neuropeptide on energy balance. For example, co-administration of NPY and AgRP has
been shown to additively increase food intake compared with each peptide alone (20).
Unfortunately, little is known regarding the concentrations of neuropeptides released or their
specific sites of action within the hypothalamus under different physiological conditions. It
is therefore currently impossible to accurately mimic physiology by administering
combinations of neuropeptides. We administered neuropeptides individually, which can
provide useful data regarding the role of these signals, but does not mimic physiological
conditions.
Continuous measurements revealed the unique food intake profiles of each neuropeptide. A
marked stimulation of food intake was seen following ICV administration of NPY and
AgRP in line with previously published data (21;22), whereas MCH and orexin-A were less
potent, resulting in a non-significant (P = 0.09) increase in food intake. Previous studies
have demonstrated a significant increase in food intake following ICV injection of MCH and
orexin at equivalent doses (2;12;23). The differing food intake profiles from our studies
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highlight the characteristics of specific neuropeptide signaling pathways. For example, ICV
administration of NPY caused an immediate and potent increase in food intake which was
relatively short-lived compared to the orexigenic effects of AgRP which only became
statistically significant 3h after injection and lasted the duration of the study. Interestingly,
AgRP caused a significant reduction in XAMB during the dark phase, 12 hours post
injection. It is possible that AgRP has similar suppressive effects on activity, as measured
using XAMB, in the light phase, but that these effects are difficult to discern against the low
activity of the control animals during this period. The mechanism by which AgRP reduces
activity is unclear and requires further investigation. The increased RER values of AgRP
injected animals likely reflect their increased food intake leading to increased use of
carbohydrate as fuel source. Aside from a slight decrease in dark phase ambulatory activity,
no discernible differences between the 1nmol and 3nmol doses of AgRP were detected. If
the experiment had continued beyond 24h it is possible that a distinction between high and
low doses may have been observed. Despite NPY and AgRP largely being secreted from the
same neurons in the Arc (24), the different food intake, activity and energy expenditure
profiles exhibited following ICV administration into rats in the present studies highlight
their distinct effects.
In rats, fasting or a reduction in food intake will usually result in a reduction in energy
expenditure as the body acts to conserve energy stores. Interestingly, following the
administration of specific neuropeptides, changes in energy expenditure were contrary to
those predicted from the observed changes in food intake alone. For example, NPY and
orexin-A both stimulated food intake, but orexin-A increased energy expenditure whilst
NPY reduced it. This coordinated metabolic response to NPY is in line with previous work
that has shown that NPY stimulates food intake, promotes white fat lipid storage and
decreases brown adipose tissue (BAT) thermogenesis (25). It is unclear how NPY decreases
energy expenditure and it is likely that multiple mechanisms are involved. NPY has been
shown to suppress sympathetic nervous system (SNS) activity to BAT (26). Furthermore,
NPY is an important regulator of the hypothalamic-pituitary-thyroid (HPT) axis which is
critical for the regulation of energy expenditure. Previous work has demonstrated the
projection of NPY neurons from the Arc to the PVH and the presence of the Y1R on TRH
neurons in the PVH (1). ICV administration of NPY has also been shown to suppress PVH
proTRH mRNA and circulating thyroid hormone levels (27). Acute changes in TRH have
been shown to influence oxygen consumption within a similar timeframe to the changes in
energy expenditure observed in the current study (28) and ICV administration of TRH
stimulates oxygen consumption, perhaps due to increased sympathetic outflow to brown
adipose tissue (BAT) (29). By contrast, the increase in VO2 following ICV administration of
orexin-A was associated with a marked increase in activity, consistent with its role in
arousal. Orexin-A neurons project to a number of extrahypothalamic regions including the
locus coeruleus, an area important in the control of arousal and anxiety-like behaviours and
c-fos activiation is seen in this nucleus following ICV administration of orexin-A. (30). In
addition to effects on arousal, orexin-A also directly increases energy expenditure by
increasing the firing rate of sympathetic nerves to BAT (31).
Unique profiles of food intake, activity and energy expenditure were also observed
following injection of α-MSH, CRF and NMU. For example, NMU demonstrated an
inhibition of food intake at 5 minutes post injection, with the effect lasting for just over an
hour. This is a rather short lived effect compared to previously published data demonstrating
a sustained reduction in food intake for 12h (5). The ICV injections in this previous study,
however, were administered at the start of the dark phase, compared to the early light phase
injections performed in the current studies, which may explain the different durations of the
anorectic effects observed. In contrast, CRF produced a more rapid and potent inhibition of
food intake lasting for at least 24 hours. Interestingly, the rapid and potent reduction in food
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intake seen following ICV administration of 3nmol CRF was accompanied by a prolonged
increase in activity lasting for up to 9 hours. The ability of CRF to alter grooming and
exploratory behavior has been well established (32;33). In addition, de Groote et al (34)
have shown ICV injection of low dose CRF (0.2nmol) stimulated behavioral changes lasting
for 4 hours. The contrasting temporal effects of CRF on food intake and activity suggest that
these responses may be regulated by different hypothalamic circuits. As opposed to the
feeding effects of CRF, which are mediated by the PVH, there is evidence to suggest that the
locomotor effects of CRF may be mediated via activation of brainstem serotonergic systems
(35). ICV administration of CRF also increased VO2, in line with previous data
demonstrating CRF stimulates sympathetic outflow to BAT (36).
The inhibitory effects of NMU on food intake have been suggested to be secondary to its
effects on behavior and the stress response. In addition to its anorexigenic effects (5), ICV
administration of NMU has also been shown to increase locomotor activity, face washing
and grooming behavior in rodents (37). These effects are thought to be mediated via the
CRF system (38) as they are absent in the CRF knockout mouse (39), and NMU has been
shown to stimulate CRF secretion from hypothalamic explants (40). It is therefore difficult
to ascertain NMU-specific effects, given the wide range of metabolic effects induced by
CRF itself. In the present study, NMU and CRF were shown to produce effects on activity
of differing durations. NMU reduced food intake for up to 1 hour 10 minutes whereas the
effects of CRF were much more prolonged, lasting for at least 24 hours. It is possible;
however, that peptide half-life may also contribute towards these differences. The
mechanisms through which NMU and CRF regulate food intake, activity and energy
expenditure require further study.
ICV administration of the α-MSH caused a marked decrease in food intake in line with
previously published data (41). This was associated with a rapid and potent increase in VO2.
Although decreased food intake would be expected to reduce energy expenditure per se, the
observed increase in VO2 is consistent with the known effects of the melanocortin system on
the HPT axis. As with NPY/AgRP neurons, POMC neurons from the Arc project onto TRH
neurons in the PVH (42) and ICV administration of α-MSH to food deprived rats potently
stimulates plasma TSH (43). Activation of the melanocortin 4 receptor (MC4R) by α-MSH
is also thought to stimulate TRH gene transcription (44). The increase in VO2 following
ICV administration of α-MSH is therefore likely to be due, at least in part, to its stimulatory
effects on TRH neurons. An additional mechanism may be via direct activation of
sympathetic outflow to brown adipose tissue (BAT); the α-MSH synthetic analogue
melanotan II (MTII) has been shown to directly stimulate sympathetic outflow to BAT and
the MC4R is expressed on BAT SNS outflow neurons (45). Interestingly, the 1nmol dose of
α-MSH significantly increased both oxygen consumption and ambulatory activity, but,
unlike the 3nmol dose, had no effect on food intake. These data suggest a dose-dependent
hierarchy of metabolic effects for α-MSH, and that the pathways controlling energy
expenditure may be more sensitive to the effects of α-MSH than those regulating food
intake. Alpha MSH binds to the MC3R and MC4R with similar affinities (46). Whilst the
role of the MC4R in the control of both food intake and energy expenditure has been
extensively studied in rodents and humans (47;48), the role of the MC3R, whilst important
(10;49), is less well established and requires further study. It is possible, however, that the
effects of α-MSH on food intake and energy expenditure are mediated by the different
receptors. Further work is required to determine the exact role of the MC3 and MC4R in
mediating the effects of αMSH on energy balance.
In summary, these data demonstrate the important quantitative and temporal differences in
the response of metabolic parameters following the administration of key hypothalamic
peptides. These studies all performed in the same experimental system, facilitate comparison
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between these neuropeptide systems and provide useful information on the time course and
latencies of specific neuropeptides. It must be considered, however, that within the
hypothalamus, neuropeptides are released in a coordinated fashion to mount an appropriate
physiological response to nutritional status. Further studies are required to elucidate the
precise neuronal pathways that allow the hypothalamus to sense changes in nutritional status
and how these are coordinated to mediate an appropriate physiological response by altering
energy intake and expenditure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
3 day baseline profiles of A) VO2 and VCO2, B) activity (XAMB and ZTOT) and C) food
intake. Food dispensers were refilled at 24h (1) and animals were food deprived at 48h (2).
Food intake was measured every minute and is presented as cumulative food intake at 30min
intervals. Horizontal activity was measured every 30min for 24h and is presented as total
number of beams broken during a 30min period. Metabolic parameters for each individually
housed animal were measured every 30min for 24h. Shaded bars represent the dark phase. n
= 21-24 per group, results are mean ± SEM.
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Figure 2.
Food Intake. The effect of a single ICV injection of hypothalamic neuropeptides at doses of
1nmol and 3nmol on food intake. Food intake was measured every minute for 24h and is
presented as a percentage of saline at 30 minute intervals. *P < 0.05 1nmol treatment group
vs. saline, #P < 0.05 3nmol treatment group vs. saline (n = 6-8/group). Saline - ●, 1nmol
dose - ▲, 3nmol dose - □. Results are mean ± SEM.
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Figure 3.
Ambulatory activity (XAMB). The effect of a single ICV injection of hypothalamic
neuropeptides at doses of 1nmol and 3nmol on XAMB. Activity was measured every 30min
for 24h and is presented as total number of horizontal beams broken during a 30min period.
*P < 0.05 1nmol treatment group vs. saline, #P < 0.05 3nmol treatment group vs. saline (n =
6-8/group). Saline - ●, 1nmol - ▲, 3nmol - □. Results are mean ± SEM.
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Figure 4.
Oxygen Consumption. The effect of a single ICV injection of hypothalamic neuropeptides at
doses of 1nmol and 3nmol on VO2. VO2 was measured every 30min for 24h. *P < 0.05
1nmol treatment group vs. saline, #P < 0.05 3nmol treatment group vs. saline (n = 6-8/
group). Saline - ●, 1nmol - ▲, 3nmol - □. Results are mean ± SEM.
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Figure 5.
Respiratory exchange ratio (RER). The effect of a single ICV injection of hypothalamic
neuropeptides at doses of 1nmol and 3nmol on RER. RER was measured every 30min for
24h. *P < 0.05 1nmol treatment group vs. saline, #P < 0.05 3nmol treatment group vs. saline
(n = 6-8/group). Saline - ●, 1nmol - ▲, 3nmol - □. Results are mean ± SEM.
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